BEGIN:VCALENDAR VERSION:2.0 PRODID:icalendar-ruby CALSCALE:GREGORIAN BEGIN:VEVENT DTSTAMP:20240329T014622Z UID:8ce7619b-7b3c-4440-9e72-d59853e6a411 DTSTART:20210917T080000 DTEND:20210918T080000 CLASS:PRIVATE DESCRIPTION:
 \;
\n\nWith the enormous response from the previous annual Tumor &am p\; Cancer Immunology conference 2020\, ConferenceSeries invites all the p articipants from all over the world to attend 3rd International Conference on Tumor &\; Cancer Immunolo gy-2020&rdquo\; during September 17-18\, 2020 in San Diego\, USA which includes prompt keynote presentations\, Oral talks\, Poster presenta tions and Exhibitions. The Tumor &\; Cancer Immunology Conference hosti ng presentations from editors of prominent refereed journals\, renowned an d active investigators and decision makers in the field of Immunology.
\n\nTumor &\; Cancer Immunology -2020 Conference de als with the diagnosis\, prevention\, and treatment of diseases of the org an specific cancers and including the latest techniques. Tumor &\; Canc er Immunology 2020 is an extraordinary event designed for International me dical health professionals and oncologists to facilitate the dissemination and application of research findings related to Cancer. Head and Neck Can cer The conference invites participants from all leading universities\, cl inical research institutions and diagnostic companies to share their resea rch experiences on all aspects of this rapidly expanding field and thereby \, providing a showcase of the latest techniques. Tumor &\; Cancer Immu nology 2020 provides two days of robust discussions on methods and strateg ies related to management and quality improvement of Cancer therapy\, Tumo r Biomarkers as well as explore new ideas and concepts on a global scale a nd the topics include breast cancer\, leukaemia\, bone cancer\, lung cance r\, prostate cancer\, thyroid cancer\, blood cancer\, colon cancer and cer vical cancer.
\n\n \;
\n\nWhy to attend??
\n\nWith members from around the world focused on learning about Tu mor or Cancer immunology and its advances: this is your best opportunity t o reach the largest assemblage of participants from Tumor &\; Cancer im munology community. conduct presentations\, distribute information&rsquo\; s\, meet with current and potential scientists\, make a splash with new dr ug developments\, and receive name recognition at this 2-day event\, world -renowned speakers\, the most recent techniques\, developments\, and the n ewest updates in Tumor &\; Cancer immunology are hallmarks of this conf erence.
\n\n \;
\n\nTarget Audience
\n \n \;
\n\nJoin us in San D iego\, USA for the leading annual Tumor &\; Cancer immunology 2020 event and
\n\nFind the latest developments in immunology and immunotherapy Lectures by the world'\;s prominent Tumor Researchers\, oncologist and poster presentations at every career stage. N etwork Tumor immunology and Immunotherapy with colleagues from more than 5 0 countries Awareness on novel tools and techniques to benefit your resear ch.
\n\n \;
\nTrack 1: Tumors
\n\nA Tumo r is an abnormal growth of body tissue. Tumors can be cancerous (malignant ) or noncancerous (benign). Tumors are of many types such as Carcinoid Tum or\, Pituitary Tumor\, and Tumor lysis syndrome. In general\, tumors occur when cells divide and grow excessively in the body. Normally\, the body c ontrols cell growth and division. New cells are created to replace older o nes or to perform new functions. Cells that are damaged or no longer neede d die to make room for healthy replacements. If the balance of cell growth and death is disturbed\, a Tumor may form. Problems with the body'\;s immune system can lead to tumors. Carcinoid tumors are of neuroendocrine o rigin and derived from primitive stem cells in the gut wall\, but they can be seen in other organs\, including the lungs\, mediastinum\, thymus\, li ver\, pancreas\, bronchus\, ovaries\, prostate\, and kidneys .Carcinoid tu mors have high potential for metastasis.
\n\n \;
\n\nA primary brain Tumor is one t hat originates in the brain\, and not all primary brain tumors are cancero us\; benign tumors are not aggressive and normally do not spread to surrou nding tissues\, although they can be serious and even life threatening. Pr imary brain tumors emerge from the various cells that make up the brain an d central nervous system and are named for the kind of cell in which they first form. The most common types of adult brain tumors are gliomas and as trocytic tumors. These tumors form from astrocytes and other types of glia l cells\, which are cells that help\, keep nerves healthy. The second most common type of adult brain tumors are meningeal tumors. These form in the meninges\, the thin layer of tissue that covers the brain and spinal cord .
\n\n \;
\n\nTrack 3: Tumor Immunology p>\n\n
The molecular classification of Tumor is actually arrangement ana lysis disguised as classification. In a typical gene expression array stud y\, the researcher will look at a cluster of tumors of a specific type. Cl uster analysis of the gene expression array values will help discrete the tumors into groups with common expression patterns. Some of these grouping s will prove to have a detailed biologic feature (e.g. increased tendency to metastasize\, higher response to a chemotherapeutic agent\, lengthened existence). Cancers are not just masses of malignant cells but complex &ls quo\;rogue&rsquo\; organs\, to which many other cells are recruited and ca n be degraded by the transformed cells. Interactions between malignant and non-transformed cells create the Tumor microenvironment (TME).
\n\n \;
\n\nTrack 4: Tumor immunotherapy research p>\n\n
Immunotherapy is an innovative treatment approach that empowers t he human immune system to overcome cancer and other debilitating diseases. The T-cell therapies are the most radical of several new approaches that recruit the immune system to attack cancers. The treatments work by removi ng molecular brakes that normally keep the body&rsquo\;s T cells from seei ng cancer as an enemy\, and they have helped demonstrate that the immune s ystem is capable of destroying cancer. Immunotherapy may help boost the bo dy&rsquo\;s immune response. This approach uses drugs/agents to trigger or stimulate the immune system to react to the invader &ndash\; in this case \, the cancer cells. This is similar to how a cold virus would stimulate y our immune system.
\n\n \;
\n\nTrack 5: Cancer Imm unology &\; Immunotherapy
\n\nImmunotherapy is treatment that uses certain parts of a person&rsquo\;s immune system to fight disea ses such as cancer. This can be done in a couple of ways: Own immune syste m stimulation\, Biological therapy or biotherapy. These advances in cancer immunotherapy are the result of long-term investments in basic research o n the immune system&mdash\;research that continues today. Additional resea rch is currently under way to: understand why immunotherapy is effective i n some patients but not in other&rsquo\;s who have the same cancer\, expan d the use of immunotherapy to more types of cancer\, increase the effectiv eness of immunotherapy by combining it with other types of cancer treatmen t\, such as targeted therapy\, chemotherapy\, and radiation therapy.
\n \n \;
\n\nTrack 6: Types of Cancer
\n\nCancer is the name given to a collection of related diseases. Cancer can start almost anywhere in the human body\, which is made up of trillions of cells. In all types of cancer\, some of the body&rsquo\;s cells begin to divide without stopping and spread into surrounding tissues. When cancer d evelops\, however\, this orderly process breaks down. As cells become more and more abnormal\, old or damaged cells survive when they should die\, a nd new cells form when they are not needed. These extra cells can divide w ithout stopping and may form growths called tumors. There are more than 10 0 types of cancer. Types of cancer are usually named for the organs or tis sues where the cancers form. For example\, lung cancer starts in cells of the lung\, and brain cancer starts in cells of the brain. Cancers also may be described by the type of cell that formed them\, such as an epithelial cell or a squamous cell.
\n\n \;
\n\nTrack 7: Can cer Research &\; Cancer
\n\nThe goal of the Cancer Rese arch Program is to make significant improvements in the prevention\, early detection\, diagnosis and treatment of cancer. It will continue to transl ate basic research findings into clinical applications together with strat egic partners\, with the National Centre for Tumor Diseases (NCT) and the nationally active German Consortium for Translational Cancer Research (DKT K) playing key roles. Most of us know about vaccines given to healthy peop le to help prevent infections\, such as measles and chicken pox. These vac cines use weakened or killed germs like viruses or bacteria to start an im mune response in the body. Getting the immune system ready to defend again st these germs helps keep people from getting infections. Most cancer vacc ines work the same way\, but they make the person&rsquo\;s immune system a ttack cancer cells.
\n\n \;
\n\nTrack 8: Antibody Therapy of Cancer
\n\nAntibody marks the cancer cell and ma kes it easier for the immune system to find. The monoclonal antibody drug rituximab (Rituxan) attaches to a specific protein (CD20) found only on B cells\, one type of white blood cell. Certain types of lymphomas arise fro m these same B cells. monoclonal antibodies can also function by attenuati ng hyperactive growth signals neo angiogenesis. A monoclonal antibody can be conjugated to a radioactive particle that will ensure directed delivery to the cancer cell and slow and long release of the radiation\, hence max imizing chances of positive outcome and minimizing non-specific damaging e xposure to radiation.
\n\n \;
\n\nTrack 9: Combini ng Cancer Immunotherapies
\n\nTargeted therapies act by blo cking essential biochemical pathways or mutant proteins that are required for tumor cell growth and survival. These drugs can arrest tumor progressi on and induce striking regressions in molecularly defined subsets of patie nts. Indeed\, the first small molecule targeted agent\, the BCR-ABL kinase inhibitor imatinib\, rapidly induced complete cytogenetic responses in 76 % of chronic myelogenous leukemia patients. Further research into the unde rlying genetic pathways driving tumor proliferation uncovered additional o ncoproteins that are critical for tumor maintenance\, such as the epiderma l growth factor receptor (EGFR)\, BRAF\, KIT\, HER (also known as neu and ERBB) and anaplastic lymphoma kinase (ALK). Similar to imatinib\, small mo lecule inhibitors of these kinases have effectuated impressive tumor respo nses in selected patients\, although regressions are commonly followed by the development of progressive disease due to the emergence of drug-resist ant variants. Resistance usually involves secondary mutations within the t argeted protein or compensatory changes within the targeted pathway that b ypass the drug-mediated inhibition. Accordingly\, targeted therapies may e licit dramatic tumor regressions\, but persistence is generally short-live d\, limiting the overall clinical benefit.
\n\n \;
\n\nImmunology- based therapy is rapidly developing into an effective treatment option for a surprising range of cancers. We have learned over the last decade that powerful immunologic effector cells may be blocked by inhibitory regulator y pathways controlled by specific molecules often called "\;immune che ckpoints."\; The development of a new therapeutic class of drugs that inhibit these inhibitory pathways has recently emerged as a potent strateg y in oncology. Three sets of agents have emerged in clinical trials exploi ting this strategy. These agents are antibody-based therapies targeting cy totoxic T-lymphocyte antigen 4 (CTLA4)\, programmed cell death 1 (PD-1)\, and programmed cell death ligand 1 (PD-L1). These inhibitors of immune inh ibition have demonstrated extensive activity as single agents and in combi nations. Clinical responses have been seen in melanoma\, renal cell carcin oma\, small cell lung cancer\, and several other tumor types.
\n\n&n bsp\;
\n\nTrack 11: Cancer Clinical Trials
\n\n< p>To developing new methods to prevent\, detect\, and treat cancer. It is through clinical trials that researchers can determine whether new treatme nts are safe and effective and work better than current treatments. Cancer clinical trials have led to scientific advances that have increased docto rs'\; understanding of how and why tumor&rsquo\;s develop and grow. Thi s knowledge has helped doctors make progress in preventing cancer\, diagno sing cancer\, slowing or stopping the development of cancer\, and finding cancers that have come back after treatment.\n\n \;
\n\n< strong>Track 12: Radiology and Imaging in Cancer
\n\nRadiology represents a branch of medicine that deals with radia nt energy in the diagnosis and treatment of dise. An imaging test is a way to let doctors see what&rsquo\;s going on inside your body. These tests s end forms of energy (like x-rays\, sound waves\, radioactive particles\, o r magnetic fields) through your body. Your body tissues change the energy patterns to make an image or picture. These pictures show how your insides look and work so that health care providers can see changes that may be c aused by diseases like cancer.
\n\n \;
\n\nTrack 1 3: Cancer Prognosis &\; Diagnosis
\n\nP rognosis of any disease means the estimate of the likely course and outcom e of the disease. Prognosis of cancers usually means the estimate of succe ss with treatment and chances of recovery. Doctors estimate prognosis by u sing statistics that researchers have collected over many years about peop le with the same type of cancer. Several types of statistics may be used t o estimate prognosis. Some common numbers that are used to determine progn osis include cancer specific survival\, relative survival\, overall surviv al\, disease-free survival etc. Cancer is nearly always diagnosed by an ex pert who has looked at cell or tissue samples under a microscope. In some cases\, tests done on the cells&rsquo\; proteins\, DNA\, and RNA can help tell doctors if there&rsquo\;s cancer. These test results are very importa nt when choosing the best treatment options. Lumps that could be cancer mi ght be found by imaging tests or felt as lumpsduring a physical exam\, but they still must be sampled and looked at under a microscope to find out w hat they really are. Not all lumps are cancer. In fact\, most tumors are n ot cancer.
\n\n \;
\n\nTrack 14: Cancer Micro and Immuno environment
\n\nInteractions between malignant and n on-transformed cells create the Tumor microenvironment (TME). The non-mali gnant cells of the TME have a dynamic and often tumor-promoting function a t all stages of carcinogenesis .Intercellular communication is driven by a complex and dynamic network of cytokines\, chemokine&rsquo\;s\, growth fa ctors\, and inflammatory and matrix remodeling enzymes against a backgroun d of major perturbations to the physical and chemical properties of the ti ssue. The evolution\, structure and activities of the cells in the TME hav e many parallels with the processes of wound healing and inflammation\, bu t cells such as macrophages are also found in cancers that have no known a ssociation with chronic inflammatory conditions.
\n\n \;
\n\nTrack 15: Stem Cell Therapy
\n\nStem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell the rapy\; Stem-cell therapy has become controversial following developments s uch as the ability of scientists to isolate and culture embryonic stem cel ls\, to create stem cells using somatic cell nuclear transfer and their us e of techniques to create induced pluripotent stem cells. For over 30 year s\, bone marrow has been used to treat cancer patients with conditions suc h as leukaemia and lymphoma\; this is the only form of stem-cell therapy t hat is widely practiced. Stem cells are being studied for a number of reas ons. The molecules and exosomes released from stem cells are also being st udied in an effort to make medications
\n\n \;
\n\nTrack 16: Tumor markers and drug targeting
\ n\nTumor markers are substances that are produced by cancer or by other cells of the body in response to cancer or certain benign (noncancerous) conditions. Most tumor markers are made by normal cells as well as by canc er cells\; however\, they are produced at much higher levels in cancerous conditions. These substances can be found in the blood\, urine\, stool\, t umor tissue\, or other tissues or bodily fluids of some patients with canc er. Most tumor markers are proteins. Thus far\, more than 20 different tum or markers have been characterized and are in clinical use. Some are assoc iated with only one type of cancer\, whereas others are associated with tw o or more cancer types. There is no &ldquo\;universal&rdquo\; tumor marker that can detect any type of cancer. Among various approaches to specifica lly target drug-loaded carrier systems to required pathological sites in t he body\, two seem to be most advanced &ndash\; passive (EPR effect-mediat ed) targeting\, based on the longevity of the pharmaceutical carrier in th e blood and its accumulation in pathological sites with compromised vascul ature\, and active targeting\, based on the attachment of specific ligands to the surface of pharmaceutical carriers to recognize and bind pathologi cal cells.
\n\n \;
\n\nTrack 17: Tumor biology
\n\nCancer cells behave as independent cells\, growing without control to form tumors. Tumors grow in a series of steps. The first step is hyperplasia\, meaning that there are too many cells resulting from unco ntrolled cell division. These cells appear normal\, but changes have occur red that result in some loss of control of growth. The second step is dysp lasia\, resulting from further growth\, accompanied by abnormal changes to the cells. The third step requires additional changes\, which result in c ells that are even more abnormal and can now spread over a wider area of t issue. These cells begin to lose their original function\; such cells are called anaplastic. At this stage\, because the tumor is still contained wi thin its original location (called in situ) and is not invasive\, it is no t considered malignant - it is potentially malignant. The last step occurs when the cells in the tumor metastasize\, which means that they can invad e surrounding tissue\, including the bloodstream\, and spread to other loc ations. This is the most serious type of tumor\, but not all tumors progre ss to this point. Non-invasive tumors are said to be benign. The discovery of tumor stem cells in a range of cancers has created opportunities for r esearchers to identify these rare cells in both solid tumors and hematolog ic cancers\, as well as to investigate the role of these cells at differen t stages of disease.The recognition that the cancer cell is in a symbiotic relationship with the tumor microenvironment has created opportunities to study the interactions of cancer cells within the tumor or the host micro environment.
\n\n \;
\n\nTrack 18:
Cancer Pharmacology focuses on developing experimental approaches to the clinical treatment of cancer through research that bridges the fields of molecular carcinogenesis\, bi ochemical pharmacology\, radiation biology\, and clinical pharmacology. span>Cancer chemotherapy and pharmacology involves the pharmacological and oncological aspects of drugs at both an experimental a nd clinical level. New anticancer drugs require screening in terms of not only their pharmacokinetic and pharmacodynamic p rofiles but also single and combined drug administration modalities as wel l as the different phases of clinical trials. Importantly preclinical toxi cology as well as drug interactions and indications for chemotherapy in ca ncer treatment are also investigated.
\n\n \;
\n\nTrack 19: Cancer Biomarkers
\n\nIn cancer research and medicine\, biomarkers are used in three primary ways:
\n\n \;
\n\nTrack 20: Cancer Genomics and Metabolomics
\n\nCanc er genomics is the study of the totality of DNA sequence and gene expressi on differences between tumor cells and normal host cells. It aims to under stand the genetic basis of tumor cell proliferation and the evolution of t he cancer genome under mutation and selection by the body environment\, th e immune system and therapeutic interventions. Metabolomics research is be ing used to discover diagnostic cancer biomarkers in the clinic\, to bette r understand its complex heterogeneous nature\, to discover pathways invol ved in cancer that could be used for new targets and to monitor metabolic biomarkers during therapeutic intervention. These metabolomics approaches may also provide clues to personalized cancer treatments by providing usef ul information to the clinician about the cancer patient&rsquo\;s response to medical interventions. The ultimate goal of most metabolomics cancer s tudies is to discover cancer-specific diagnostic\, prognostic or predictiv e biomarkers for a patient.
\n\n \;
\n\nTrack 21: Cancer &\; HIV
\n\nPeople infected with HIV have a subst antially higher risk of some types of cancer compared with uninfected peop le of the same age. Three of these cancers are known as "\;acquired im munodeficiency syndrome (AIDS)-defining cancers"\; or "\;AIDS-defi ning malignancies"\;: Kaposi sarcoma\, non-Hodgkin lymphoma\, and cerv ical cancer. A diagnosis of any one of these cancers marks the point at wh ich HIV infection has progressed to AIDS. A compromised immune system can increase a person&rsquo\;s risk for cancer. It can also allow for cancer c ells to spread faster than in someone without HIV. With the use of antiret roviral therapy (ART)\, the rates of AIDS-related cancers have dropped sig nificantly. At the same time\, people with HIV are at higher than average risk for several other cancers\, including Hodgkin lymphoma and cancers of the anus\, lung\, liver\, and skin\, The number of cases of these other c ancers is increasing in people with HIV.
\n\n \;
\n\nT he immune system is the body&rsquo\;s natural defence system. It is a coll ection of organs\, cells and special molecules that helps protect you from infections\, cancer and other diseases. Immuno-oncology therapies activat e our immune system\, making it able to recognise cancer cells and destroy them. Breast cancer is one of the major cancer types for which new immune -based cancer treatments are currently in development. Lung cancer surgery carries risks\, including bleeding and infection. Clinical trials are stu dies of experimental lung cancer treatments. Adult central nervous system tumor is a disease in which abnormal cells form in the tissues of the brai n and/or spinal cord. A tumor that starts in another part of the body and spreads to the brain is called a metastatic brain tumor. There are differe nt types of brain and spinal cord tumors such as Astrocytic Tumors\, Oligo dendroglial Tumors\, Mixed Gliomas\, Ependymal Tumors\, Medulloblastomas\, Pineal Parenchymal Tumors\, Meningeal Tumors\, Germ Cell Tumors\, Craniop haryngiom. Advances in Immuno-oncology have given oncologists and their pa tients reason to be encouraged&mdash\;the launch of immune checkpoint inhi bitors and development of other immunotherapy assets for the treatment of several difficult-to-treat diseases\, including metastatic melanoma and no n-small cell lung cancer\, represents great progress.
\n\n \;
\n\nTrack 23: Novel Approaches in Cancer &\; Tumor
\n\nImmunotherapy encompasses several different treatment approache s\, each of which has a distinct mechanism of action\, and all of which ar e designed to boost or restore immune function in some manner. This includ es: Monoclonal antibodies\, Immune checkpoint inhibitors\, Therapeutic Can cer vaccines\, cytokines\, and other non-specific immunotherapies.
\n\n \;
\n\nPlease contact the event manager Marilyn (maril yn.b.turner@nyeventslist.com ) below for: - Multiple participant discounts - Price quotations or visa invitation letters - Payment by alternate chan nels (PayPal\, check\, Western Union\, wire transfers etc) - Event sponsor ships NO REFUNDS ALLOWED ON REGISTRATIONS Service fees included in this li sting. ----------------------------------------------------------------- T his event is brought to you by: Conference Series - NewYorkEventsList http ://www.NyEventsList.com http://www.BostonEventsList.com http://www.SFBayEv entsList.com ------------------------------------------------------------- ---- MYL180502CEV MYL180629UPA
\n